「霆升科技」获近亿元B+轮融资，已开展首例4D ICE人体临床研究｜36氪首发

Core Viewpoint - Ting Sheng Technology has recently completed nearly 100 million yuan in B+ round financing, which will be used for the research and clinical investment of 4D intracardiac ultrasound (4D ICE) products, laying the foundation for future mass production [1] Company Overview - Since 2019, Ting Sheng Technology has been developing intracardiac ultrasound imaging technology (ICE), which allows for real-time imaging by inserting an ultrasound probe into the heart through blood vessels, avoiding interference from skin and chest structures [1] - The company has obtained 4 out of 7 registered certifications from the National Medical Products Administration for its products, indicating a strong position in the domestic market [1] Market Dynamics - The market for 2D ICE products is expected to see more domestic companies entering within the next 1-2 years, but early approved companies may capture over 85% of the core market share due to domestic entry barriers and clinical usage habits [1] - The 4D ICE product, with its higher technical barriers, is anticipated to have greater market potential, providing precise imaging guidance for various surgical scenarios [2] Technical Challenges - Developing 4D ICE products involves overcoming significant technical challenges, including ASIC chip development and the establishment of a high-end transducer manufacturing system, which requires substantial investment [2][3] - The cost of a single ASIC design and tape-out is approximately over 10 million yuan, and the construction of a high-end transducer manufacturing system requires at least 50 million yuan [3] Clinical Development - Ting Sheng Technology completed its first human clinical study of 4D ICE in April this year, marking a significant milestone in its product development [3] Leadership and Investment Perspectives - The CEO of Ting Sheng Technology emphasized that the successful development of 4D ICE represents a significant advancement in cardiovascular interventional imaging technology, enhancing the company's competitiveness in the global market [4] - Investors view the company as a leading player in the intracardiac ultrasound field, highlighting its strong technical capabilities and innovative potential, which are crucial for achieving domestic replacement in the market [5]